Jessica Fye
Stock Analyst at JP Morgan
(4.47)
# 295
Out of 5,154 analysts
216
Total ratings
63.97%
Success rate
14.1%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $18.81 | +59.49% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $19.69 | +32.05% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $35.48 | -29.54% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $13.04 | +76.38% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $182.01 | +9.33% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $67.37 | -3.52% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $52.52 | -52.40% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $101.50 | +18.23% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $320.66 | +47.51% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $18.97 | +300.63% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $95.94 | -7.23% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $61.12 | +94.70% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $240.65 | +9.70% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $456.69 | +16.05% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $301.12 | +27.86% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $74.04 | +8.05% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $38.23 | +36.02% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $86.30 | -10.78% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $28.63 | +22.25% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $140.13 | -3.66% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $478.16 | -30.99% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.48 | +53.30% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.97 | +51.65% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $30.55 | -1.80% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $70.70 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.29 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.72 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.06 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.90 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.71 | +309.36% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.98 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.54 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $18.81
Upside: +59.49%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $19.69
Upside: +32.05%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $35.48
Upside: -29.54%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $13.04
Upside: +76.38%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $182.01
Upside: +9.33%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $67.37
Upside: -3.52%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $52.52
Upside: -52.40%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $101.50
Upside: +18.23%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $320.66
Upside: +47.51%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $18.97
Upside: +300.63%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $95.94
Upside: -7.23%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $61.12
Upside: +94.70%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $240.65
Upside: +9.70%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $456.69
Upside: +16.05%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $301.12
Upside: +27.86%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $74.04
Upside: +8.05%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $38.23
Upside: +36.02%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $86.30
Upside: -10.78%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $28.63
Upside: +22.25%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $140.13
Upside: -3.66%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $478.16
Upside: -30.99%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.48
Upside: +53.30%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.97
Upside: +51.65%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $30.55
Upside: -1.80%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $70.70
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.29
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.72
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.06
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.90
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.71
Upside: +309.36%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $9.98
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $13.54
Upside: -